ERBB2 and triple-negative breast carcinoma: CpG island promoter methylation is more common in young women with high-grade pathology and triple-negative breast cancer (negative estrogen receptor, negative progesterone receptor, negative ERBB2 [Her2/Neu]) [79,80,81,82].